Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Transl Med
Hlavní autoři: Yang, Lu, Zhang, Youyou, Shan, Weiwei, Hu, Zhongyi, Yuan, Jiao, Pi, Jingjiang, Wang, Yueying, Fan, Lingling, Tang, Zhaoqing, Li, Chunsheng, Hu, Xiaowen, Tanyi, Janos L., Fan, Yi, Huang, Qihong, Montone, Kathleen, Dang, Chi V., Zhang, Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/
https://ncbi.nlm.nih.gov/pubmed/28747513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky